Market closed
Mural Oncology plc/$MURA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Ticker
$MURA
Sector
Trading on
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
109
Website
MURA Metrics
BasicAdvanced
$62M
Market cap
-
P/E ratio
-$9.12
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$62M
52-week high
$6.25
52-week low
$2.88
Average daily volume
194K
Financial strength
Current ratio
7.377
Quick ratio
7.13
Long term debt to equity
2.357
Total debt to equity
5.482
Management effectiveness
Return on assets (TTM)
-85.30%
Return on equity (TTM)
-183.89%
Valuation
Price to book
0.36
Price to tangible book (TTM)
0.36
Price to free cash flow (TTM)
-0.436
Growth
Earnings per share change (TTM)
-22.53%
What the Analysts think about MURA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mural Oncology plc stock.
MURA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MURA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MURA News
AllArticlesVideos
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
GlobeNewsWire·3 weeks ago
Mural Oncology to Participate in Two Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mural Oncology plc stock?
Mural Oncology plc (MURA) has a market cap of $62M as of December 15, 2024.
What is the P/E ratio for Mural Oncology plc stock?
The price to earnings (P/E) ratio for Mural Oncology plc (MURA) stock is 0 as of December 15, 2024.
Does Mural Oncology plc stock pay dividends?
No, Mural Oncology plc (MURA) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Mural Oncology plc dividend payment date?
Mural Oncology plc (MURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Mural Oncology plc?
Mural Oncology plc (MURA) does not currently have a Beta indicator.